Alnylam Pharmaceuticals Stock Rating Lowered by Morgan Stanley (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, StockRatingsNetwork.com reports. They currently have a $54.00 price objective on the stock, down from their previous price objective of $72.00. Morgan Stanley’s price target points to a potential downside of 39.84% from the company’s current price.
The analysts wrote, “We view Alnylam’s technology as potentially transformative and see the prospects for the drugs that have been tested in humans as robust,” the report noted. “In addition, we view the recent Sanofi/Sirna transactions as steps that likely will help maximize the platform from many perspectives. However, in light of the recent stock strength over the past 12 mos, we see a more balanced risk/reward for shares heading into the major TTR program data catalysts in 2H14. Above- expectations TTR data in 2H14 or human proof of concept from an earlier-stage program (e.g. hemophilia) are events that would trigger a valuation re-evaluation.”
ALNY has been the subject of a number of other recent research reports. Analysts at S&P Equity Research downgraded shares of Alnylam Pharmaceuticals to a “neutral” rating in a research note to investors on Monday. Separately, analysts at JMP Securities reiterated a “market perform” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Thursday, January 9th. They now have a $67.00 price target on the stock. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $66.14.
In other Alnylam Pharmaceuticals news, Director Paul Schimmel unloaded 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $85.36, for a total transaction of $1,280,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 3.77% on Tuesday, hitting $89.76. 1,437,745 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 52-week low of $20.70 and a 52-week high of $112.57. The stock has a 50-day moving average of $64.43 and a 200-day moving average of $55.73. The company’s market cap is $5.693 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 46.4% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.38 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.